Hiberix FDA Approval History
FDA Approved: Yes (First approved August 19, 2009)
Brand name: Hiberix
Generic name: Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
Dosage form: Solution for Intramuscular Injection
Company: GlaxoSmithKline
Treatment for: Haemophilus influenzae Prophylaxis
Hiberix is a vaccine indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b. Hiberix is approved for use in children aged six weeks through four years of age (prior to fifth birthday).
Development timeline for Hiberix
| Date | Article |
|---|---|
| Jan 14, 2016 | Approval FDA Approves Expanded Use of GSK Hib Vaccine From Booster Dose To Full Series |
| Aug 20, 2009 | Approval FDA Approves GSK's Hib Vaccine, Hiberix |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.